Brand and Other Names:Qvar
- Classes: Corticosteroids, Inhalants
Dosing & Uses
Dosage Forms & Strengths
No prior history of inhaled corticosteroid use: 40-80 mcg inhaled PO BID; do not exceed 320 mcg BID
Prior history of inhaled corticosteroid use: 40-160 mcg inhaled PO BID; do not exceed 320 mcg BID
Prime inhaler (2 actuations into air) before first use and after prolonged idleness (>10 days)
Dosage Forms & Strengths
<5 years: Safety and efficacy not established
5-12 years: 40 mcg inhaled PO BID for patients with/without prior history of inhaled corticosteroid use; do not exceed 80 mcg inhaled BID
- No prior history of inhaled corticosteroid use: 40-80 mcg inhaled PO BID; do not exceed 320 mcg BID
- Prior history of inhaled corticosteroid use: 40-160 mcg inhaled PO BID; do not exceed 320 mcg BID
May cause growth velocity reduction with extended use; monitor closely if on prolonged therapy
<5 years: Use with spacer device is not recommended
Start at lower end of dosing range due to increased risk of adverse effects
Serious - Use Alternative
Significant - Monitor Closely
Increased asthma symptoms (2-4%)
Oral symptoms (2-3%)
Psychiatric events and behavioral changes (eg, aggression, depression, sleep disorders, psychomotor hyperactivity, and suicidal ideation [primarily in children])
Primary treatment of status asthmaticus, acute bronchospasm
Respiratory tract TB
Untreated fungal or bacterial infections
Ocular herpes simplex
Nasal septum perforation
Risk for more serious or fatal course of chickenpox or measles in susceptible patients (eg, unvaccinated or immunologically unexposed individuals); care must be taken to avoid exposure
Deaths have occurred due to adrenal insufficiency following abrupt withdrawal of oral steroids; taper withdrawal gradually
May decrease growth velocity in children
Risk of infections of nose and pharynx, including Candida albicans; must rinse mouth after inhalation to reduce risk
Risk of bronchospasm with immediate increase in wheezing after administration; if this occurs, discontinue therapy and administer SABA immediately
Excessive use may suppress HPA function; monitor closely, especially postoperatively or during periods of stress
During periods of stress or severe status asthmaticus, may require supplementary systemic corticosteroids immediately; patient should carry warning card indicating possible need for supplementary systemic steroids in such emergencies
Switching from systemic steroids to therapy may unmask allergic conditions (eg, conjunctivitis, eczema, rhinitis)
Prolonged corticosteroid use may result in elevated IOP, glaucoma, and/or cataracts
Not a bronchodilator; should not be administered for rapid relief of acute bronchospasm
Pregnancy & Lactation
Pregnancy category: C
Lactation: Potential for excretion into milk; use only if benefits greatly outweigh risks
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Potent anti-inflammatory glucocorticoid; inhibits inflammatory cells and release of inflammatory mediators
Bioavailability: 20% systemic
Onset: 1-3 weeks
Duration: 6 hr
Peak plasma concentration: 88 pg/mL
Protein binding: 94-96% over concentration range of 1000-5000 pg/mL
Prodrug; rapidly activated by hydrolysis to active monoester (17-BMP)
Half-life: 30 minutes (17-BMP: 2.8 hr)
Excretion: Feces (major), urine (<10%)
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs